Dalian CITIC Pharmaceutical Co., Ltd.

This study employed a single-center, non-randomized, open-label trial design to evaluate the pharmacokinetic characteristics and safety of levonornidazole sodium chloride injection (levonornidazole, specification: 100 ml: levonornidazole 0.25 g and sodium chloride 0.825 g) produced by Shijiazhuang No. 4 Pharmaceutical Co., Ltd. and licensed by Beijing Jinyaoyuan Pharmaceutical Research Institute, in patients with pelvic anaerobic bacterial infections treated with multiple intravenous administrations. The Cmax ss/MIC90 after patients reached steady state was calculated to provide a basis for clinical medication regimens for patients with pelvic anaerobic bacterial infections.

This multicenter, non-randomized, open-label, single-arm study evaluated the efficacy, safety, treatment course, and dosage characteristics of levonornidazole sodium chloride injection (levonornidazole, specification: 100 ml: levonornidazole 0.25 g and sodium chloride 0.825 g) produced by Shijiazhuang No. 4 Pharmaceutical Co., Ltd. and licensed by Beijing Jinyaoyuan Pharmaceutical Research Institute, in treating pelvic anaerobic bacterial infections under diverse clinical settings.